<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277249</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#12-001241</org_study_id>
    <nct_id>NCT02277249</nct_id>
  </id_info>
  <brief_title>Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion</brief_title>
  <official_title>Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion: a Pilot Study of Patient Preference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current practice for the provision of late second trimester abortion (dilation and
      evacuation, or D&amp;E) often involves the administration of digoxin into the fetal compartment
      to induce fetal demise prior to the procedure. Digoxin may be administered transabdominally
      or transvaginally into the fetal compartment. Both modes of administration have been shown in
      prospective studies to be highly effective and safe. Both modes of administration are
      considered standard of care. This pilot study will directly compare transabdominal and
      transvaginal digoxin with respect to patient preference (i.e, patient pain score describing
      discomfort with injection).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Discomfort With Digoxin Injection (Pain Score)</measure>
    <time_frame>At time of study (immediate)</time_frame>
    <description>Pain score (indicated by patient reporting pain level from 0 (&quot;no hurt&quot;) to 5 (&quot;hurts worst&quot;) at time of digoxin injection)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>Transvaginal digoxin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transabdominal digoxin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin (transvaginal administration)</intervention_name>
    <description>Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
    <arm_group_label>Transvaginal digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin (transabdominal administration)</intervention_name>
    <description>Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
    <arm_group_label>Transabdominal digoxin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Singleton viable gestation

          -  Identifying as primarily English-speaking

          -  Body mass index less than 40 kilograms/meters squared

          -  Already a consented patient for second-trimester abortion procedure with digoxin to be
             performed for termination of pregnancy at the study site

          -  No medical contraindication to digoxin (i.e., no cardiac dysfunction, no renal
             dysfunction, no hypersensitivity to digoxin)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <results_first_submitted>February 8, 2016</results_first_submitted>
  <results_first_submitted_qc>August 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transvaginal Digoxin</title>
          <description>Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transvaginal administration): Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
        <group group_id="P2">
          <title>Transabdominal Digoxin</title>
          <description>Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transabdominal administration): Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transvaginal Digoxin</title>
          <description>Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transvaginal administration): Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
        <group group_id="B2">
          <title>Transabdominal Digoxin</title>
          <description>Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transabdominal administration): Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="6.7"/>
                    <measurement group_id="B2" value="26.6" spread="6.1"/>
                    <measurement group_id="B3" value="26.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="1.2"/>
                    <measurement group_id="B2" value="21.4" spread="1.6"/>
                    <measurement group_id="B3" value="21.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Births</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.8"/>
                    <measurement group_id="B2" value="0.87" spread="1.2"/>
                    <measurement group_id="B3" value="0.83" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kilograms/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="5.0"/>
                    <measurement group_id="B2" value="26.7" spread="4.8"/>
                    <measurement group_id="B3" value="27.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Discomfort With Digoxin Injection (Pain Score)</title>
        <description>Pain score (indicated by patient reporting pain level from 0 (&quot;no hurt&quot;) to 5 (&quot;hurts worst&quot;) at time of digoxin injection)</description>
        <time_frame>At time of study (immediate)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transvaginal Digoxin</title>
            <description>Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transvaginal administration): Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
          </group>
          <group group_id="O2">
            <title>Transabdominal Digoxin</title>
            <description>Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transabdominal administration): Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Discomfort With Digoxin Injection (Pain Score)</title>
          <description>Pain score (indicated by patient reporting pain level from 0 (&quot;no hurt&quot;) to 5 (&quot;hurts worst&quot;) at time of digoxin injection)</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="1.33"/>
                    <measurement group_id="O2" value="1.88" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No power calculation performed given that this was a pilot study. The null hypothesis was that there would be no difference in pain score with injection between the two study arms. The Wilcoxon rank sum test was selected because of the study's small sample size and the non-normal distribution of pain scores. Intention to treat analyses were used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transvaginal Digoxin</title>
          <description>Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transvaginal administration): Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
        <group group_id="E2">
          <title>Transabdominal Digoxin</title>
          <description>Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
Digoxin (transabdominal administration): Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a &quot;Procedure/Surgery&quot; type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was crossover between treatment arms (4 subjects in the transvaginal group received transabdominal digoxin). This study is limited by its small sample size and attendant statistical power.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Instructor - Department of Obstetrics and Gynecology</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>3107942257</phone>
      <email>priyabatra@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

